APA (7th ed.) Citation

Kasper-Virchow, S., Hofheinz, R., Stintzing, S., Dechow, T., Ettrich, T., Sinn, M., . . . Goetze, T. (2024). LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316). Annals of Oncology, 35, S1218. https://doi.org/10.1016/j.annonc.2024.08.2264

Chicago Style (17th ed.) Citation

Kasper-Virchow, S., et al. "LBA25 Randomized Phase III Trial of Ramucirumab in Combination with TAS102 (Trifluridin/Tipiracil) Vs. TAS102 Monotherapy in Heavily Pretreated Metastatic Colorectal Cancer: The RAMTAS/IKF643 Trial of the German AIO (AIO-KRK-0316)." Annals of Oncology 35 (2024): S1218. https://doi.org/10.1016/j.annonc.2024.08.2264.

MLA (9th ed.) Citation

Kasper-Virchow, S., et al. "LBA25 Randomized Phase III Trial of Ramucirumab in Combination with TAS102 (Trifluridin/Tipiracil) Vs. TAS102 Monotherapy in Heavily Pretreated Metastatic Colorectal Cancer: The RAMTAS/IKF643 Trial of the German AIO (AIO-KRK-0316)." Annals of Oncology, vol. 35, 2024, p. S1218, https://doi.org/10.1016/j.annonc.2024.08.2264.